Cebaracetam

Cebaracetam
Clinical data
Other namesCGS-25248; ZY-15119
ATC code
  • None
Legal status
Legal status
  • US: Unscheduled and not FDA approved
Identifiers
  • 4-[2-[4-(4-Chlorophenyl)-2-oxopyrrolidin-1-yl]acetyl]piperazin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H18ClN3O3
Molar mass335.79 g·mol−1
3D model (JSmol)
  • C1CN(CC(=O)N1)C(=O)CN2CC(CC2=O)C3=CC=C(C=C3)Cl
  • InChI=1S/C16H18ClN3O3/c17-13-3-1-11(2-4-13)12-7-15(22)20(8-12)10-16(23)19-6-5-18-14(21)9-19/h1-4,12H,5-10H2,(H,18,21) X markN
  • Key:QPKMIYNBZGPJAR-UHFFFAOYSA-N X markN
  (verify)

Cebaracetam (INNTooltip International Nonproprietary Name; developmental code names CGS-25248; ZY-15119) is an experimental drug of the racetam group described as a nootropic which was never marketed.

It is a chlorinated acetylpiperazine-substituted analogue of phenylpiracetam and is also a derivative of RGPU-95 (4-chlorophenylpiracetam). It is the analogue of RGPU-95 in which the terminal amide group has been replaced with a piperazin-2-one moiety. The mechanism of action of cebaracetam is undefined or unknown.

The drug was under development by Novartis for the treatment of cognition disorders by the 1990s but development was discontinued in 1995. It reached phase 2 clinical trials prior to its discontinuation.

See also

References

  1. 1 2 3 4 "Cebaracetam". AdisInsight. 23 May 1995. Retrieved 1 October 2024.
  2. ↑ "Stem Book 2018" (PDF). cdn.who.int. 2018. Retrieved 13 Oct 2025.
  3. ↑ Chollet D, Künstner P (June 1992). "Fast systematic approach for the determination of drugs in biological fluids by fully automated high-performance liquid chromatography with on-line solid-phase extraction and automated cartridge exchange. Application to cebaracetam in human urine". Journal of Chromatography. 577 (2): 335–340. doi:10.1016/0378-4347(92)80255-o. PMID 1400764.
  4. 1 2 "Cebaracetam". PubChem. Retrieved 1 October 2024.